Human adenovirus detection in rural community water sources in central-west Brazil Graziela Picciola Bordoni1,*ORCID iD , Lucas Candido Gonçalves Barbosa2ORCID iD , Fernando Santos Lima1ORCID iD , Thais Reis Oliveira2ORCID iD , José Daniel Gonçalves Vieira1ORCID iD , Paulo Sergio Scalize3ORCID iD , Lilian Carla Carneiro1,2

https://www.academia.edu/3143-0481/2/3/10.20935/AcadImmunoDis8447 Introduction: Poor and limited access to improved water, sanitation and hygiene (WASH) services, common in rural communities in developing countries, may lead to a high burden of enteric infections and the spread of fecal organisms. In the absence of a public water distribution network, rural areas obtain their water supply from surface and/or groundwater sources, where microbial quality is often unknown. Because adenoviruses are highly persistent in water and widely distributed in the environment, they have become an important group of enteric viruses and may potentially be involved in waterborne outbreaks. https://www.academia.edu/3143-0481/2/3/10.20935/AcadImmunoDis8447?email_action=download

Challenging the Confines of Risk of Recurrence in High-Risk HR+/HER2- Early Breast Cancer Authors: Joyce A. O’Shaughnessy, MD; Priya Rastogi, MD; Seth Wander, MD, PhD

https://www.medscape.org/viewarticle/challenging-confines-risk-recurrence-high-risk-hr-her2-early-2026a1000bq3?page=1&src=mkmcmr_driv_stan_mscpedu_261023-OUS-HONC-challenging-confines-risk-recurrence-high-risk-hr-her2-early-2026a1000bq3-cta&uac=148436CN

Year-long trial finds NAD-boosting supplement fails to improve early Parkinson's symptoms (+++ +++ +++ +++)

Year-long trial finds NAD-boosting supplement fails to improve early Parkinson's symptoms https://www.news-medical.net/news/20261012/Year-long-trial-finds-NAD-boosting-supplement-fails-to-improve-early-Parkinsons-symptoms.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Year-long trial finds NAD-boosting supplement fails to improve early Parkinson's symptomsIn a phase 3 randomized clinical trial involving 410 people with early Parkinson disease, 52 weeks of nicotinamide riboside supplementation increased blood NAD levels but failed to improve clinical outcomes compared with placebo. Participants receiving the supplement had modestly worse overall disease scores, although the difference was below the threshold generally considered clinically meaningful. People who walk more each day tend to score better on several brain tests https://www.news-medical.net/news/20261014/People-who-walk-more-each-day-tend-to-score-better-on-several-brain-tests.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 People who walk more each day tend to score better on several brain testsResearchers analyzed 14 years of physical activity and blood pressure records from 3,093 US adults and found that higher daily step counts were associated with better performance on tests of attention, cognitive control, and reward-related decision-making. Higher systolic blood pressure was associated with poorer delay-discounting performance, but accounted for only 4. Epilepsy linked to higher risk of young-onset dementia https://www.news-medical.net/news/20261014/Epilepsy-linked-to-higher-risk-of-young-onset-dementia.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Epilepsy linked to higher risk of young-onset dementiaPeople with epilepsy may be more likely to develop young-onset dementia than people without epilepsy, according to a study published October 14, 2026, in Neurology®, the medical journal of the American Academy of Neurology. Hybrid AI architecture improves seizure prediction using EEG signals https://www.news-medical.net/news/20261013/Hybrid-AI-architecture-improves-seizure-prediction-using-EEG-signals.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Hybrid AI architecture improves seizure prediction using EEG signalsEpilepsy affects about 50 million people worldwide and can seriously affect patients' quality of life. Electroencephalography (EEG), which records the brain's electrical activity in real time, plays an important role in epilepsy diagnosis and monitoring. Recurrent brain tumors undergo unique genetic changes after treatment https://www.news-medical.net/news/20261014/Recurrent-brain-tumors-undergo-unique-genetic-changes-after-treatment.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Recurrent brain tumors undergo unique genetic changes after treatmentWhen patients are diagnosed with certain brain tumors, one of the biggest unanswered questions is what happens when the cancer returns. 16-year study links worsening vision to higher dementia risk https://www.news-medical.net/news/20261011/16-year-study-links-worsening-vision-to-higher-dementia-risk.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 16-year study links worsening vision to higher dementia riskResearchers followed 15,576 older adults in Hong Kong for up to 16 years and linked moderate to severe visual impairment to higher dementia risk, with rapid visual decline strengthening the association at poorer levels of vision. They estimated that severe impairment corresponded to 2.1 fewer dementia-free years over the study period, but could not establish that correcting vision prevents dementia. Study finds both the liver and brain drive distinct symptoms of rare genetic epilepsy https://www.news-medical.net/news/20261009/Study-finds-both-the-liver-and-brain-drive-distinct-symptoms-of-rare-genetic-epilepsy.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Study finds both the liver and brain drive distinct symptoms of rare genetic epilepsyA recent study from Johns Hopkins Medicine reveals that both the liver and brain contribute pathways to differing symptoms of the same rare inherited disorder. Routine blood test may offer clues to future dementia risk https://www.news-medical.net/news/20261009/Routine-blood-test-may-offer-clues-to-future-dementia-risk.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Routine blood test may offer clues to future dementia riskA common blood test already carried out during routine health checks may contain clues about a person's long-term risk of dementia, according to research being presented at the ECNP Congress in Munich and recently published in the Journal of Alzheimer's Disease. Study uncovers a protective role for microglia in Parkinson's disease https://www.news-medical.net/news/20261007/Study-uncovers-a-protective-role-for-microglia-in-Parkinsons-disease.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Study uncovers a protective role for microglia in Parkinson's diseaseResearchers at the University of Oxford have uncovered a previously unrecognized protective role for microglia, the brain's resident immune cells, in Parkinson's disease. Study reveals how different plant saponins alleviate ischemic stroke https://www.news-medical.net/news/20261012/Study-reveals-how-different-plant-saponins-alleviate-ischemic-stroke.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Study reveals how different plant saponins alleviate ischemic strokeIschemic stroke accounts for approximately 85% of all strokes and remains a major cause of death and long-term disability. Study links abnormal immature astroglia to lower fluid intelligence in older epilepsy patients https://www.news-medical.net/news/20261020/Study-links-abnormal-immature-astroglia-to-lower-fluid-intelligence-in-older-epilepsy-patients.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Study links abnormal immature astroglia to lower fluid intelligence in older epilepsy patientsA new USC-led study links abnormal immature astroglia, star-shaped cells that support brain function, to lower fluid intelligence, or the ability to solve new problems, in older adults with epilepsy. Adults with ADHD face higher risk of developing dementia later in life https://www.news-medical.net/news/20261007/Adults-with-ADHD-face-higher-risk-of-developing-dementia-later-in-life.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Adults with ADHD face higher risk of developing dementia later in lifeA new study led by University of Pittsburgh School of Medicine researchers finds that adults with attention-deficit/hyperactivity disorder (ADHD) face a significantly higher risk of developing dementia or mild cognitive impairment later in life.

Plasma eMTBR-Tau: Advancing Blood-Based Tau Tangle Research

https://spear.bio/resource/blog/plasma-emtbr-tau-tangle-biomarker/?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Explore how plasma eMTBR-Tau complements pTau 217 in Alzheimer’s research. Discover findings generated using Spear Bio’s SPEAR TrueDetect™ eMTBR-Tau assay, linking blood measurements to autopsy-confirmed tau pathology, tau PET, and cognitive decline—with strong classification performance across blood samples collected up to a decade before death.

Women and men face different heart attack risks with diabetes

https://www.news-medical.net/news/20261023/Women-and-men-face-different-heart-attack-risks-with-diabetes.aspx A study spanning four decades reveals how cholesterol abnormalities and high blood pressure help explain differences in diabetes-related heart attack risk between women and men, with warning signs emerging years before diabetes is diagnosed. A study published in European Heart Journal Open reported that the relative increase in myocardial infarction, or heart attack, risk associated with diabetes was similar in women and men after adjustment for conventional cardiovascular risk factors. The initially observed sex difference narrowed after adjustment for these factors, whose combined contribution was greater in women than in men.

Maqui Berry: Health Benefits, Nutrition, and Uses (+++)

Maqui Berry: Health Benefits, Nutrition, and Uses https://www.news-medical.net/health/Maqui-Berry-Health-Benefits-Nutrition-and-Uses.aspx From its purple pigments to its interactions with gut bacteria, maqui berry raises scientific questions about how plant compounds influence cellular defenses and human health. The maqui berry, which grows in the temperate rainforests of southern Chile and Argentina, has a higher anthocyanin content than many other berries.1,9 Historically, Mapuche communities in southern Chile used maqui preparations, particularly those made from leaves, for wound care and fever, with modern researchers increasingly exploring this fruit as a source of antioxidant compounds.1 Jaboticaba Fruit: What Are Its Potential Health Benefits? https://www.news-medical.net/health/Jaboticaba-Fruit-What-Are-Its-Potential-Health-Benefits.aspx Beneath jaboticaba’s dark-purple skin lies a mixture of fiber and plant compounds that raises questions about digestion, blood sugar, and the gap between laboratory findings and human health. Jaboticaba is a dark-purple fruit that grows directly on the trunks and branches of trees native to the Brazilian Atlantic Forest. Emerging evidence suggests that anthocyanins, ellagitannins, and other bioactive compounds in jaboticaba may influence inflammatory pathways and the gut microbiota, primarily in laboratory and animal studies.1,3,7 How GLP-1 Drugs Affect the Brain Beyond Weight Loss https://www.news-medical.net/health/How-GLP-1-Drugs-Affect-the-Brain-Beyond-Weight-Loss.aspx What happens when a metabolic treatment reaches the brain's appetite, reward, and memory systems? Researchers are examining where these effects begin and what they could mean for neurological care. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) were initially designed to improve glycemic control in people with type 2 diabetes. Research now suggests that these drugs may also influence mood, reward processing, cognition, and processes implicated in neurodegenerative diseases.1

Scientists studied one million immune cells and found clues to future disease risk

https://www.news-medical.net/news/20261022/Scientists-studied-one-million-immune-cells-and-found-clues-to-future-disease-risk.aspx A sweeping analysis of the body's most abundant white blood cells examines how their molecular differences relate to serious illness, metabolic health, and the risk of future disease. A recent study published in the journal Nature Immunology presents a single-cell atlas of human neutrophils (SCAHN), offering new insights into how these immune cells behave in health and disease. The researchers linked neutrophil gene activity patterns to cancer outcomes, metabolic health, and the risk of death over the long term. These patterns also helped identify mortality risk among individuals with acute illness at hospital presentation. The findings suggest that neutrophil profiling may eventually contribute to clinical risk assessment, pending prospective validation.

Sharing the Decision of Treatment Planning in High-Risk HR+/HER2- Early Breast Cancer Authors: Shaheenah Dawood, MBBCh, MPH, FACP

https://www.medscape.org/viewarticle/sharing-decision-treatment-planning-high-risk-hr-her2-early-2026a1000f67?page=1&src=mkmcmr_driv_stan_mscpedu_261022-OUS-HONC-sharing-decision-treatment-planning-high-risk-hr-her2-early-2026a1000f67-cta&uac=148436CN

FDA grants traditional approval for pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for unresectable or metastatic TMB-H solid tumors with updated indication

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph?utm_medium=email&utm_source=govdelivery On October 16, 2026, the Food and Drug Administration granted traditional approval to pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) for adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥13 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.

A microglial transition could mean the difference between a healthy brain and Alzheimer’s disease Some people with amyloid plaques and tau tangles in their brain never develop Alzheimer’s disease. New research suggests it comes down to microglial activity. Written byAllison Whitten, PhD

A microglial transition could mean the difference between a healthy brain and Alzheimer’s disease Some people with amyloid plaques and tau tangles in their brain never develop Alzheimer’s disease. New research suggests it comes down to microglial activity. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/a-microglial-transition-could-mean-the-difference-between-a-healthy-brain-and-alzheimer-s-disease-17273?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_qwl0FiYdzQ0FjoF5pHFPPnwt1-88MP98J41WMyAvrK2bw2GVkJC7D-Ujak870yfzN5TIVKxxvnHuN3QfXiMv16ggafg&_hsmi=445381586&utm_content=445381586&utm_source=hs_email Whether or not someone develops Alzheimer’s disease could be the result of a key transition in microglial activity, according to new research published recently in Nature Medicine. Researchers led by Mark Fiers and Bart De Strooper at the VIB-KU Leuven Center for Neuroscience and University College London, in collaboration with Muna Therapeutics, found that microglia switch from an early inflammatory response in the presence of amyloid plaques to an antigen-presenting state that coincides with the development of tau tangles. Fiers told DDN that the work “started from an observation that has mystified the field for years: Many people have a brain full of amyloid but never get dementia.” The research team wanted to use spatial transcriptomics techniques to specifically study what goes on in the brain around amyloid plaques. Their work revealed that the postmortem brains of octogenarians and centenarians who did not show cognitive symptoms of Alzheimer’s disease — despite having the classic pathology in their brains — diverged in their patterns of microglial resilience.

Could overlooked bacterial DNA help explain aggressive prostate cancer? Bacterial genomes recovered from discarded DNA sequencing data could help researchers investigate whether microbes contribute to aggressive prostate cancer. Written byBree Foster, PhD

Could overlooked bacterial DNA help explain aggressive prostate cancer? Bacterial genomes recovered from discarded DNA sequencing data could help researchers investigate whether microbes contribute to aggressive prostate cancer. Written byBree Foster, PhD https://www.drugdiscoverynews.com/could-overlooked-bacterial-dna-help-explain-aggressive-prostate-cancer-17595 When researchers sequence DNA from a tumor or blood sample, they typically focus on the patient's genetic material. Sequences that do not map to the human genome are often filtered out, but researchers are increasingly recognizing that these unmapped sequences actually contain a wealth of valuable information. A growing body of evidence has linked certain bacteria to cancer, with some microbes implicated in cancer development and others associated with disease progression. Now, researchers at the University of East Anglia (UEA) have investigated whether this overlooked DNA could help uncover previously uncharacterized bacterial species in patients with prostate cancer.

Moving beyond single targets in neurological repair Neuro-Innovators is testing whether a combination of existing medicines can promote neuroplasticity and improve outcomes for people living with chronic stroke disability. Written byBree Foster, PhD

Moving beyond single targets in neurological repair Neuro-Innovators is testing whether a combination of existing medicines can promote neuroplasticity and improve outcomes for people living with chronic stroke disability. Written byBree Foster, PhD https://www.drugdiscoverynews.com/moving-beyond-single-targets-in-neurological-repair-17486?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-84vh7nMnqBm_u_j5cWuYWwR2LB3ayuwP5bDn4TmL9jTrTE07waLIhOe5plsoVw0cSuLMmcot2yPPWTIo4jHb5J0A70sA&_hsmi=445381586&utm_content=445381586&utm_source=hs_email Stroke is a leading cause of long-term disability worldwide, leaving many survivors with persistent impairments despite advances in acute treatment and rehabilitation. A key determinant of post-stroke recovery is the brain’s ability to reorganize its structure and function following injury, known as neuroplasticity. This process involves a complex network of interacting mechanisms, including changes in synaptic connections, neural circuitry, blood vessel formation, and inflammation. However, harnessing these separate mechanisms is extremely difficult.

A tuberculosis vaccine could hold clues to tackling dementia BCG vaccination reduced tau pathology and neuroinflammation in mice, prompting researchers to investigate whether trained immunity could inform future treatments for Alzheimer’s disease. Written byBree Foster, PhD

A tuberculosis vaccine could hold clues to tackling dementia BCG vaccination reduced tau pathology and neuroinflammation in mice, prompting researchers to investigate whether trained immunity could inform future treatments for Alzheimer’s disease. Written byBree Foster, PhD https://www.drugdiscoverynews.com/a-tuberculosis-vaccine-could-hold-clues-to-tackling-dementia-17597 First administered to a human infant in 1921, the Bacillus Calmette–Guérin (BCG) vaccine was developed to protect against tuberculosis. More than a century later, BCG remains the only licensed vaccine against tuberculosis and is now used for a range of conditions, including leprosy and bladder cancer. Now, researchers are investigating whether the vaccine could also treat neurodegenerative disease. Several retrospective studies have linked BCG treatment for bladder cancer with a lower incidence of dementia, although these findings cannot establish that the vaccine itself is responsible. In a new study, researchers at Johns Hopkins University School of Medicine explored this connection in mice with tauopathy, a group of brain disorders characterized by the abnormal accumulation of tau protein.

FDA approves GSK's functional cure for hepatitis B Clinical trial updates, regulatory approvals, and more led the news this week. Brought to you byDDN editorial team

FDA approves GSK's functional cure for hepatitis B Clinical trial updates, regulatory approvals, and more led the news this week. Brought to you byDDN editorial team https://www.drugdiscoverynews.com/fda-approves-gsk-s-functional-cure-for-hepatitis-b-17600 Tuesday brought good news for many patients with chronic hepatitis B. GSK’s antisense oligonucleotide Hibsago (bepirovirsen) injection received the green light from the FDA, effectively offering a chance for some people with chronic hepatitis B to stop taking their antivirals entirely. The approval was based on two Phase 3 B-WELL trials, which demonstrated that 24 percent of patients who received the Hibsago treatment qualified to stop taking their medications — compared to zero percent taking the placebo. After 24 weeks without antivirals, Hibsago led to a functional cure in 19 percent of patients who no longer had detectable viral proteins in their blood. “Hibsago provides a new treatment approach that gives some patients the possibility of maintaining control of the virus after all chronic HBV treatment has ended. This approval represents an important advance for people living with this serious disease,” said Wendy Carter, Acting Director of the Office of Infectious Diseases in the Center for Drug Evaluation and Research, in the press release. The approval marks the first to reach the finish line in a competitive landscape, with therapeutic options for hepatitis B from companies like Brii Biosciences now lagging behind. – Allison Whitten

Navigating Next Steps in CLL: A Collaborative Dialogue Authors: Chaitra Ujjani, MD

https://www.medscape.org/viewarticle/navigating-next-steps-cll-collaborative-dialogue-2026a1000i1d?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_261022-OUS-HONC-navigating-next-steps-cll-collaborative-dialogue-2026a1000i1d-cta

Most Read Cancer Science & Oncogenesis (+...)

https://read.qxmd.com/collection/1133?ecd=wnl_readmost_261023

Comment p1674 Mitapivat in the RISE UP trial: a new therapy for sickle cell disease Jennifer Knight-Madden,Zachary Ramsay (+...)

Comment p1674 Mitapivat in the RISE UP trial: a new therapy for sickle cell disease Jennifer Knight-Madden,Zachary Ramsay https://www.thelancet.com/journals/lancet/issue/vol408no10565/PIIS0140-6736(26)X2040-2

FDA Approves New Formulation of Sjörgen’s Disease Treatment by Madaline Spencer| Published on: Oct 23, 2026

https://checkrare.com/fda-approves-new-formulation-of-sjorgens-disease-treatment/ The US Food and Drug Administration (FDA) has approved Evoxac (cevimeline HCI) oral solution to address dry mouth in patients with Sjögren’s disease (SjD). SjD is an autoimmune disorder that largely impacts secretory glands. It is also associated with rheumatic disorders such as rheumatoid arthritis or systemic lupus erythematosus. Hallmark symptoms include dry mouth and dry eyes, but the condition may cause skin, nose, and vaginal dryness. SjD may also affect other organs of the body including the kidneys, blood vessels, lungs, liver, pancreas, and brain.

Know Your Nutrition

Understanding the Nutrition Facts Label, the Updated “Healthy” Claim, and Other Nutrition Claims